On Friday 3 October, the European Commission announced that, at the request of 14 participating countries, it had signed a joint procurement framework contract with the Spanish pharmaceutical company HIPRA.
This agreement will enable participating countries to order up to 4 million doses of protein-based Covid-19 vaccine Bimervax®, adapted to the LP.8.1 variant. Orders will be placed according to national needs, with no minimum purchase required.
The contract, valid for up to two years,...